Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma
Status:
Recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, prospective clinical study of the efficacy and safety of
Orelabrutinib maintenance therapy after Autologous Stem Cell Transplantation (ASCT) in
patients with primary central nervous system lymphoma.